1	Genetic risk factors and Covid-19 severity in Brazil: results from BRACOVID
2	Study
3	
4	Alexandre C. Pereira <sup>1,2*</sup> , Taniela Marli Bes <sup>2,3</sup> , Mariliza Velho <sup>1</sup> , Emanuelle Marques <sup>1</sup> ,
5	Cintia E Jannes <sup>1</sup> , Karina Ramos Valino <sup>1</sup> , Carla L Dinardo <sup>4</sup> , Silvia Figueiredo Costa <sup>3</sup> ,
6	Alberto José da Silva Duarte <sup>5</sup> , Alexandre Ricardo dos Santos <sup>6</sup> , Miguel Mitne-Neto <sup>6</sup> , Jose
7	Medina-Pestana <sup>7</sup> , Jose E Krieger <sup>1</sup> *
8	
9	
10	<sup>1</sup> Laboratorio de Genetica e Cardiologia Molecular, Instituto do Coracao (InCor),
11	Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
12	<sup>2</sup> Genetics Department, Harvard Medical School, MA, USA
13	<sup>3</sup> Divisao de Doenças Infecciosas, Hospital das Clínicas da Universidade de São Paulo,
14	São Paulo, Brazil.
15	<sup>4</sup> Immunohematology, Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo,
16	Brazil.
17	<sup>5</sup> Departamento de Dermatologia, Laboratório de Dermatologia e Imunodeficiências,
18	Faculdade de Medicina e Instituto de Medicina Tropical de São Paulo, Sao Paulo, Brazil.
19	<sup>6</sup> Grupo Fleury, Sao Paulo, Brazil
20	<sup>7</sup> Hospital do Rim, UNIFESP, Sao Paulo, Brazil
21	
22	
23	*Corresponding author.
24	E-mail: <u>alexandre.pereira@incor.usp.br</u> (ACP), <u>j.krieger@hc.fm.usp.br</u> (JEK)
25	

- 26
- 27
- 28 29

# 30 Abstract:

The Covid-19 pandemic has changed the paradigms for disease surveillance and rapid deployment of scientific-based evidence for understanding disease biology, susceptibility, and treatment. We have organized a large-scale genome-wide association study in Sars-Cov-2 infected individuals in Sao Paulo, Brazil, one of the most affected areas of the pandemic in the country, itself one of the most affected in the world. Here we present the results of the initial analysis in the first 5,233 participants of the BRACOVID study.

We have conducted a GWAS for Covid-19 hospitalization enrolling 3533 cases (hospitalized Covid-19 participants) and 1700 controls (non-hospitalized Covid-19 participants). Models were adjusted by age, sex and the 4 first principal components. A meta-analysis was also conducted merging BRACOVID hospitalization data with the Human Genetic Initiative (HGI) Consortia results.

42 BRACOVID results validated most loci previously identified in the HGI meta-analysis. 43 In addition, no significant heterogeneity according to ancestral group within the Brazilian 44 population was observed for the two most important Covid-19 severity associated loci: 45 3p21.31 and Chr21 near IFNAR2. Using only data provided by BRACOVID a new genome-wide significant locus was identified on Chr1 near the genes DSTYK and 46 47 RBBP5. The associated haplotype has also been previously associated with a number of 48 blood cell related traits and might play a role in modulating the immune response in 49 Covid-19 cases.

- 50
- 51
- 52
- 53

- 54 Introduction
- 55

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first described in Wuhan, China, in December 2019, and quickly spread across the globe causing a pandemic (1). After 20 months of the beginning of the spread, there were more than 213 million confirmed cases worldwide, with total deaths exceeding 4 million, half million in Brazil alone (2).

61 Clinical outcomes of SARS-CoV-2 infection range from asymptomatic infection 62 to fatal coronavirus disease 2019 (Covid-19). The high mortality rates are predominantly 63 among specific subgroups with predeterminate conditions, such as male sex, older age or 64 having pre-existent cardiovascular, pulmonary, or immune disease. However, many 65 severe clinical cases are not due to comorbidity or constitutional factors. Notably, even among those without pre-existing conditions, inter-individual heterogeneity is striking. 66 67 The considerable variation in disease behavior among infected individuals highlights the 68 importance of the hosts' genetic background modulating disease presentation (3-5).

69 Until now a small number of large-scale genome-wide association studies 70 (GWAS) has been conducted with some reproducible identified genetic loci associated 71 with disease susceptibility or severity. A GWAS among 1980 patients from the European 72 Covid-19 epicenters in Italy and Spain, as well as from the less-burdened countries of 73 Germany and Norway was the first study to describe the susceptibility locus at the 74 chromosome 3p21.31 gene cluster and suggested the involvement of the ABO blood-75 group system in Covid-19 (6). The GenOMICC study, in addition to replicating the 76 association at chromosome 3p21.31 as mediator of critical illness, identified associations 77 with disease severity and other genetic variants (7). Finally, early in 2021, the Covid-19 78 Host Genetics Initiative (HGI) has brought together 49.562 cases and 2 million controls, 79 from populations with different ancestries across the world to elucidate the genetic 80 determinants of SARS-CoV-2 infection and severity including 853 samples from the 81 BRACOVID study. From these analyses 15 genome-wide significant loci associated with 82 SARS-CoV-2 infection or Covid-19 were observed (8).

84	Despite these efforts, the still limited number of identified loci that appears to
85	modulate the relationship between clinical severity and human genetic variation
86	precludes a thoroughly understanding of inter-individual susceptibility in the disease. In
87	addition, most studies are overwhelmingly represented by European or Asian individuals
88	and whether the identified loci are also operant on individuals from other ancestry
89	backgrounds is unknown. Here we present the results from the BRACOVID study
90	enrolling 5,233 participants with distinct COVID-19 clinical presentations and from a
91	diverse population in Brazil. Our results confirm most previously identified loci and add
92	a new genome-wide significant locus associated with COVID-19 hospitalization in the
93	Brazilian population.
94	
95 06	Results
96 97	The BRACOVID study was designed to identify and characterize genetic risk
98	factors for Covid-19 severity in the Brazilian population.
99	
100	Relationship between demographic and clinical factors with Covid-19
101	hospitalization
102	
102 103	We summarize the demographic, clinical and laboratory characteristics of the
102 103 104	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity.
102 103 104 105	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity.
<ol> <li>102</li> <li>103</li> <li>104</li> <li>105</li> <li>106</li> </ol>	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. Genome-Wide Association Analysis of Covid-19 hospitalization
102 103 104 105 106 107	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. Genome-Wide Association Analysis of Covid-19 hospitalization
<ol> <li>102</li> <li>103</li> <li>104</li> <li>105</li> <li>106</li> <li>107</li> <li>108</li> </ol>	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. <b>Genome-Wide Association Analysis of Covid-19 hospitalization</b> We have performed a GWAS of the genetic association architecture regarding
<ol> <li>102</li> <li>103</li> <li>104</li> <li>105</li> <li>106</li> <li>107</li> <li>108</li> <li>109</li> </ol>	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. <b>Genome-Wide Association Analysis of Covid-19 hospitalization</b> We have performed a GWAS of the genetic association architecture regarding Covid-19 hospitalization need. Groups were 1,700 individuals that did not require
102 103 104 105 106 107 108 109 110	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. <b>Genome-Wide Association Analysis of Covid-19 hospitalization</b> We have performed a GWAS of the genetic association architecture regarding Covid-19 hospitalization need. Groups were 1,700 individuals that did not require hospital admission due to Covid-19 and 3,533 individuals hospitalized due to severe
102 103 104 105 106 107 108 109 110 111	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. <b>Genome-Wide Association Analysis of Covid-19 hospitalization</b> We have performed a GWAS of the genetic association architecture regarding Covid-19 hospitalization need. Groups were 1,700 individuals that did not require hospital admission due to Covid-19 and 3,533 individuals hospitalized due to severe Covid-19. In the primary analysis, we have run 2 GWAS analysis (one for each used
102 103 104 105 106 107 108 109 110 111 112	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. <b>Genome-Wide Association Analysis of Covid-19 hospitalization</b> We have performed a GWAS of the genetic association architecture regarding Covid-19 hospitalization need. Groups were 1,700 individuals that did not require hospital admission due to Covid-19 and 3,533 individuals hospitalized due to severe Covid-19. In the primary analysis, we have run 2 GWAS analysis (one for each used genotyping array). Each analysis was adjusted for the first 4 Principal Components, age,
<ol> <li>102</li> <li>103</li> <li>104</li> <li>105</li> <li>106</li> <li>107</li> <li>108</li> <li>109</li> <li>110</li> <li>111</li> <li>112</li> <li>113</li> </ol>	We summarize the demographic, clinical and laboratory characteristics of the 5,233 participants of the study in Table 1 according to hospitalization necessity. <b>Genome-Wide Association Analysis of Covid-19 hospitalization</b> We have performed a GWAS of the genetic association architecture regarding Covid-19 hospitalization need. Groups were 1,700 individuals that did not require hospital admission due to Covid-19 and 3,533 individuals hospitalized due to severe Covid-19. In the primary analysis, we have run 2 GWAS analysis (one for each used genotyping array). Each analysis was adjusted for the first 4 Principal Components, age, and sex. GWAS results were then merged using the meta-analysis routine in plink. The

In our main analysis, we observed one genome-wide significant locus that reached the pre-defined genome-wide significant level of 5 x  $10^{-8}$  (Figure 1). We also observed four additional loci that reached the pre-defined p-value threshold of 1 x  $10^{-6}$  (Table 2 and Supplementary Figure 1). We have run sensitivity analysis stratifying individuals by their main genetic ancestral component and then conducting a trans-ethnic meta-analysis. Results were very similar to those observed in the main analysis (Supplementary Figures 2 and 3).

122

## 123 BRACOVID HGI meta-analysis:

124

We have replicated most previously described HGI (8) (B1 analysis) results (BRACOVID was not part of this specific HGI sub-analysis) (Supplementary File 2). Specifically, both loci at 3p21.31 and Chr21 near IFNAR2 previously associated with hospitalization need on HGI B1 analysis were nominally significant in our study with the same directionality of effect. We have also compared our results to those described by HGI B2 analysis. We have observed significant associations in all previously described genome-wide loci but for the one on chr9, near the ABO locus (Supplementary File 3).

In addition to looking for replicated signals within our results, we ran two metaanalyses between BRACOVID hospitalization need and HGI B1 and B2 analysis. Adding our results to those provided by HGI B1 analysis disclosed a genome-wide association signal on chr6 that was only previously seen on the HGI B2 analysis, strengthening the confidence that this locus is indeed associated with Covid-19 severity (Supplementary File 4 and Supplementary Figure 4).

138 Our results meta-analyzing BRACOVID summary statistics with HGI B2 results supported most previously described genome-wide association loci. Namely, for Chr1 139 140 near THBS3; Chr3 LZTFL1-CXCR6; Chr6 HLA-DRB1; Chr6 FOXP4; Chr11 MUC5B; 141 Chr11 ELF5; Chr12 OAS2; Chr12 P2RX2; Chr17 CRHR1; Chr19 POLD1; Chr19 142 TYK2; and Chr21 IFNAR2 regions we were able to observe concordant signals and no 143 heterogeneity of effects. We want to emphasize the observation of significant 144 heterogeneity for the previously described loci on Chr9 ABO locus; Chr21 SLC5A3; and 145 Chr17 TAC4 suggesting that these may indeed be false-positive associations due to 146 population structure confounding, population-specific loci or loci associated with Covid-

147 19 susceptibility and not severity (Supplementary File 5).

148

# Local association structure suggests a population specific effect for Chr1 DSTYK locus:

151

152 The newly identified genome-wide significant locus near DSTYK was not 153 observed as significantly associated in our HGI meta-analysis. By comparing the local 154 association structure at the DSTYK locus, it is interesting to note that HGI B2 results also 155 suggest a sub-genome-wide significant association at the same region (Figure 2A and B). 156 However, albeit in the same recombination interval, there is no significant colocalization 157 of the two genetic association structures, suggesting (1) the existence of more than one 158 causal variants within this region or (2) that different LD structures among human 159 populations may be confounding the association pattern at this locus.

160 To explore these scenarios, we have first analyzed the local association structure 161 within the Brazilian sample stratifying by different degrees of European, African, and 162 Native American genetic ancestry among participants. Curiously, although the signal is 163 shared among the 3 groups, the strongest association signal was observed among the 164 Brazilian individuals with high European genetic ancestry (Figure 2C). In addition to this, 165 we have studied the pairwise LD between the most associated SNV in the Brazilian analysis (rs11240388), and the most associated SNV in HGI B2 analysis (rs9661015). 166 167 Strikingly different world-wide pairwise LD patterns are observed among these 2 168 markers (Figure 2F, https://ldlink.nci.nih.gov/). In our sample, the R-square between the 169 two markers was 0.32 for participants with high European ancestry, and 0.11 for 170 participants with high African ancestry.

Using only individuals with high European ancestry from our Brazilian dataset we delineated the associated haplotype boundaries between chr1:205131352 and chr1:205210329, defining a haplotype of approximately 79Kb. Looking into the haplotype structure of markers part of the associated haplotype we did not observe a significant difference in their pairwise LD structure among Brazilians with high European or high African ancestry. Using rs11240388 as a tag-SNP for our risk 177 haplotype, we defined world-wide allele frequencies for the risk haplotype (Figure 2G, 178 https://popgen.uchicago.edu/ggv/). In our own sample, the frequency of the G allele (risk 179 allele) was 48% for the entire sample, 42% in Brazilian individuals with high European 180 ancestry and 59% in Brazilian individuals with high African ancestry. Despite having 181 increased frequency in Brazilian individuals with high African ancestry, and as expected 182 from the stratified local association plots, the haplotype was only significantly associated 183 with Covid-19 severity in Brazilian individuals with high European genetic ancestry. 184 Taken together these results suggest that the causal variant responsible for the association 185 is present in a 79Kb haplotype derived from European populations.

186

# rs11240388 is also associated with several blood cell traits and with DSTYK and RBBP5 gene expression levels:

189

190 Exploring the genomic annotations for the newly observed locus associated with 191 Covid-19 hospitalization we used rs11240388 as a proxy of the risk haplotype for it is in 192 complete LD with all the markers of the 79Kb haplotype. Rs11240388 is located at 193 chr1:205208489 within the DSTYK gene region. The region appears to be delimited by a 194 recombination region spanning the genes CNTN2, TMEM81, RBBP5, DSTYK, and 195 TMCC2 and harbors several GeneHancer regulatory elements, most notably for CNTN2, 196 DSTYK and TMCC2 (Figure 3A). Querying the MR-base database for other phenotypes 197 previously shown to be associated with rs11240388, we observed 69 traits (Figure 3B). 198 Of particular interest to Covid-19 biology are blood cell related traits and lung associated 199 traits (Supplementary File 6).

200 Next, we explored the association structure between rs11240388 and GTEx gene 201 expression levels in all tissues and for all genes within the region (Figure 3C). Results 202 from GTEx suggest that rs11240388 is an eQTL in several tissues for CNTN2, 203 TMEM81, RBBP5 and DSTYK. Colocalization analysis between GTEx association 204 results and BRACOVID association results confirmed a significant colocalization for 205 these genes in several different tissues, suggesting that the association between the 79Kb 206 risk haplotype and Covid-19 severity might be mediated through gene expression 207 modulation in the genes located in this genomic region (Figure 3D). Finally, we tested all pair-wise possibilities for colocalization: BRACOVID signal, the 69 associated traits for the same region, and all GTEx gene-tissue results with significant colocalization (higher than 0.7) with BRACOVID (Supplementary Figure 5). This analysis provides several potential intermediate mediators that could explain the association between the identified risk haplotype and Covid-19 severity (Figure 3E).

213

214 Discussion

Covid-19 has been a world-wide pandemic for more than one year. The disease has killed more than 4 million individuals and has de-stabilized entire health systems as well as the world economy (2,9,10). One striking characteristic of the disease is the large inter-individual variability regarding its severity, ranging from asymptomatic to fatal. Although several identified factors influence disease severity, predicting the overall Covid-19 outcome in a particular individual remains a challenge (3–5).

Since the beginning of the pandemic, several groups worldwide have joined efforts to uncover host factors. The Host Genetic Initiative (HGI) included researchers and samples from different parts of the globe to focus on the inter-individual variability in disease presentation (8) and outcomes and the BRACOVID is currently the largest such effort in Latin America.

BRACOVID was designed to compare individuals with mild or asymptomatic Covid-19 with those with severe Covid-19 requiring hospitalization. This contrasts with most genetic studies on host determinants of Covid-19, that use individuals from the general population as their main control group. As such, BRACOVID has a more specific study protocol aimed at identifying host genetic determinants of disease severity, and not susceptibility.

The results here presented replicate most, but not all, previously reported genomewide significant loci associated with Covid-19 severity. These came from 3 prior publications: The Severe Covid-19 GWAS Group , *GenOMICC* and HGI (6–8). It is interesting to note that despite the large sample sizes, none of these prior studies have in fact compared individuals with mild versus severe Covid-19. As such, our results confirm some of the initial results regarding Covid-19 genetic determinants in a more diverse population and, most importantly, within a study design to differentiate between markers 239 of susceptibility to infection and predictors of severity. Also of importance, although 240 BRACOVID has participated in the meta-analysis of both *GenOMICC* and HGI, due to 241 the analytical plan of these two prior publications, the contrast used by BRACOVID was 242 not the one presented here. Specifically, in both GenOMICC and HGI, BRACOVID 243 summary statistics were obtained by comparing hospitalized Covid-19 individuals with 244 individuals from the general Brazilian population (the last group, not included in the 245 present analysis) on what is called the HGI B2 analysis. Even in this latter situation, 246 BRACOVID sample of hospitalized individuals used in the last version of HGI analysis, 247 the one used in our meta-analysis with HGI B2, was of only 853 individuals, in contrast 248 to the more than 3,500 hospitalized participants used in the present report.

249 Besides the importance of showing replications to previously identified loci in an 250 admixed population, understanding loci that do not replicate might also be important in 251 the follow-up efforts to identify population specific determinants of Covid-19 severity. 252 One of the loci that was not replicated in our analysis is the association signal initially 253 identified in the ABO locus. Our results, together with the verification of intense 254 heterogeneity in signal described by HGI, suggest that the association initially described 255 at this locus may be due to confounding by population structure or other higher order 256 effects.

257 We have observed a new genome-wide significant locus associated with Covid-19 258 in our population. It is comprised by a 79Kb haplotype located on chromosome 1 near the 259 DSTYK gene. The association signal in our sample was only observed in individuals with 260 high European ancestry and was not described by previous studies, suggesting it might 261 harbor a population specific risk allele or haplotype. Indeed, leveraging data from the 262 1000G project (11), we observed great inter-population differences in the haplotype 263 frequency (although an apparently constant LD structure in the region among human 264 populations).

Leveraging data from GTEx we were able to associate this haplotype with gene expression levels of at least 5 genes: DSTYK, TMEM81, RBBP5, CNTN2 and TMCC2. In addition, exploring prior publicly available GWAS data we found significant associations between the identified risk haplotype and 69 different traits (8). From these, using colocalization analysis, we have observed significant colocalization between BRACOVID results and several of these 69 traits, most strikingly a number ofhematological traits, including immune cell morphology and number.

The main limitation of this study is the lack of a suitable replication sample for the GWAS results. The observed genome-wide significant locus near DSTYK needs to be replicated in an independent sample to continue to be considered a modulator of Covid-19 severity. The continuous effort to increase the sample size of the BRACOVID study may allow the identification genome-wide significant loci with decreased effect size.

Taken together, our analysis supports the hypothesis that the identified 79Kb haplotype on chromosome 1 may modulate Covid-19 relevant immunological traits through the gene expression of at least one of the genes with significant eQTLs in the region.

282

283 Materials and methods

284

- 285 Study population
- 286

The study sample belongs to the BRACOVID Study. For the present analysis we used the first 5,233 participants enrolled in the study.

289 The BRACOVID study was designed to identify and characterize genetic risk 290 factors for Covid-19 severity in the Brazilian population. Participants were selected 291 through two different ascertainment processes. First, Covid-19 patients were enrolled 292 after hospitalization in one of the following tertiary care centers in the metropolitan area 293 of Sao Paulo, Brazil: Instituto do Coração, and Instituto Central do Hospital das Clínicas 294 da Faculdade de Medicina da Universidade de São Paulo. Non-hospitalized cases were 295 selected by serological studies surveys for previous SARS-CoV-2 infection or SARS-296 CoV-2 PCR test among health professionals or the general population.

After signing an informed consent, a sample of whole-blood already collected for in-hospital biochemical analysis or SARS-CoV-2 serology was used for genomic DNA extraction. 300 Participants responded to a detailed questionnaire aimed at collecting 301 demographic, risk factors, symptoms, and prior clinical information. For hospitalized 302 participants we extracted the data from the hospital EHR.

- 303
- 304

# 305 SNP Genotyping and Imputation

306

Genomic DNA extraction has been previously described (12). BRACOVID DNA samples were genotyped using two different Axiom arrays: Axiom\_PMRA.r3 array (N=2605) or the Axiom\_sarscov array (N=2628) (ThermoFisher, Waltham, USA) and genotypes annotated using the array specific annotation file provided at the ThermoFisher website. Genotype calling was performed using Affymetrix Power Tools. Initial VCF file contained 850483 (for the PMRA array) and 779972 (for the Sars-Cov array) variants before quality control filtering.

314 Imputation was performed using the Haplotype Reference Consortium Michigan 315 Imputation Server using the TOPMED reference haplotype panel as reference (for mixed 316 samples). More specifically, the Michigan Imputation Server used Minimac4 to conduct 317 imputation on 658,357 SNPs remaining after data quality control. After imputation data 318 were exported in the standard PLINK format, downstream QC procedures and statistical 319 analysis were conducted using the latest PLINK 320 (http://pngu.mgh.harvard.edu/\_purcell/plink) and R software packages (http://www.r-321 project.org/), installed on a Linux based computation resource. Specifically, imputation 322 markers were kept if  $R^2 > 0.3$ , and minor allele frequency (MAF) > 0.01. A HWE pvalue  $<1 \times 10^{-20}$  was used to control for potential genotyping clustering problems. 323 324 Genetic population structure was determined through PCA analysis after LD-pruning of 325 associated markers (see also Statistical Analysis section). A total of 11,395,074 SNPs 326 were used for genome-wide analyses, 10,981,197 for autosomal, and 413,877 for X-327 chromosomal analysis.

328

#### 329 GWAS Analysis

We used a dichotomous category defined among SARS-CoV-2 participants. We have grouped individuals that did not require hospitalization into the control group (participants ascertained through population-based serological prevalence studies that did not have a prior history of hospitalization due to Covid-19) and hospitalized individuals (ascertained at the first hospital admission day) in the case group. Baseline categorical parameters are presented using frequencies (proportions), continuous parameters are presented using mean  $\pm$  SD.

338 Genome-wide association analyses were conducted using plink. We have 339 conducted two analyses one without any further adjustment and one adjusting for the first 340 four principal components, age, sex, and array type. The threshold for genome-wide 341 significance was set to  $p < 5 \times 10^{-8}$ . Associations with  $p < 1 \times 10^{-6}$  were considered as 342 suggestive and presented as a list of top associated SNPs.

343 Due to the high level of admixture and complex genetic population structure 344 present in the Brazilian population we have conducted different sensitivity analysis 345 taking into consideration the individual position on the PCA plot generated using the 2 346 first principal components. Briefly, for the PCA-defined subgroup analysis we have k-347 means clustering with k=3 and defined three different subgroups with higher European, 348 African, and Native-American ancestries. Meta-analysis used a fixed-effect model and 349 was calculated using plink –meta-analysis routine.

Local association plots were created using LocusZoom (13). Local linkage disequilibrium
structure was determined using Haploview (14).

352

## 353 PheWas analysis

354

After identifying SNV that could be proxies of the associated haplotype we have used MR-base through the R package *ieugwasr* to search for prior GWAS studies reporting significant levels of association between a trait and the selected tag-SNV. The used p value cut-off level for this phewas analysis was  $p < 1 \times 10^{-5}$ .

359

#### 360 Colocalization analysis

362 For colocalization analysis we have defined a window spanning 400Kb centered 363 at the most associated variant in all regions classified as having a suggestive association 364 signal. Information on all variants within this region was used for colocalization testing. 365 We have used the R package *coloc* for colocalization analysis. Briefly, all genes residing 366 in each selected region with their expression quantitative trait loci (eQTL) summary 367 statistics available in GTEx V8.0 were sequentially tested for colocalization with the 368 results obtained for Covid-19 severity association. As reference LD structure we used 369 1000 genomes 2012 European LD matrix (our sample has approximately 80% European 370 ancestry). Colocalization was tested against all 48 tissues available in GTEx V8.0 and 371 against all traits with significant association to the selected variant (as described in the 372 phewas section). We used a threshold of H4 (the posterior probability that a single causal variant, or haplotype, could explain the local association pattern of both tested traits) > 373 374 0.7 as evidence for significant colocalization.

375

## 376 Acknowledgements

377 The BRACOVID project received an unrestricted financial support from JBS S.A. 378 Company, Sao Paulo, Brazil and from the general public under the HC-COMVIDA 379 crowdfunding scheme (https://viralcure.org/c/hc). The funds were managed by Fundação 380 Zerbini and Fundação Faculdade de Medicina, respectively. We are thankful for the infra-381 structure support for sample collection provided by the HCFMUSP Covid-19 Study 382 Group. We are also grateful to the Host Genetic Initiative for making their data publicly 383 available (full found acknowledgements can be at 384 https://www.covid19hg.org/acknowledgements/).

385

#### 386 **Conflict of interest**

387	The	authors certify that they have NO affiliations with or involvement in any
388	organ	nization or entity with any financial interest in the subject matter or materials
389	discu	ssed in this manuscript.
390		
391	Refe	rences
392	1.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
393		Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
394	2.	COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE)
395		at Johns Hopkins University (JHU) [Internet]. 2021. Available from:
396		https://coronavirus.jhu.edu/map.html
397	3.	Morens DM, Fauci AS. Emerging Pandemic Diseases: How We Got to COVID-
398		19. Cell. 2020;183(3):837.
399	4.	Casanova J-L, Abel L. Lethal Infectious Diseases as Inborn Errors of Immunity:
400		Toward a Synthesis of the Germ and Genetic Theories. Annu Rev Pathol. 2021
401		Jan;16:23–50.
402	5.	Casanova JL, Abel L. The human genetic determinism of life-threatening
403		infectious diseases: genetic heterogeneity and physiological homogeneity? Hum
404		Genet [Internet]. 2020;139(6-7):681-94. Available from:
405		https://doi.org/10.1007/s00439-020-02184-w
406	6.	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N
407		Engl J Med. 2020;383(16):1522–34.
408	7.	Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al.
409		Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591(7848):92-
410		8.
411	8.	Ganna A, Unit TG, General M. The COVID-19 Host Genetics Initiative, a global
412		initiative to elucidate the role of host genetic factors in susceptibility and severity
413		of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020;28(6):715-8.
414	9.	Weinstein M, Skinner J. Covid-19 — Implications for the Health Care System
415		David. N Engl J Med. 2011;362(5):567–71.
416	10.	Allain-Dupré D, Chatry I, Michalun V, Moisio A. The territorial impact of

417		COVID-19: managing the crisis across levels of government. OECD Tackling
418		Coronavirus. 2020. p. 2–44.
419	11.	Altshuler DL, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, et
420		al. A map of human genome variation from population-scale sequencing. Nature.
421		2010;467(7319):1061–73.
422	12.	Preparation S, No DP. Axiom <sup>TM</sup> 2.0 gDNA Sample Preparation [Internet]. p. 2–5.
423		Available from: https://www.thermofisher.com/us/en/home/technical-
424		resources/contact-us.html?supportType=TS
425	13.	Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, et
426		al. LocusZoom.js: Interactive and embeddable visualization of genetic association
427		study results. Bioinformatics. 2021 Mar;
428	14.	Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD
429		and haplotype maps. Bioinformatics. 2005 Jan;21(2):263-5.
430		
431	Supp	orting Information

**Tables:** 

433 Table 1. Demographic, clinical and laboratory characteristics of studied subjects434 according to hospitalization need.

Patients' characteristics	Total n (%)	Hospitalization n (%)	Non-hospitalization n (%)
	5233 (100)	3533 (67.5)	1700 (32.5)
Demographic characteristics			
Age categories			
<18	5 (0.1)	5 (0.1)	O (O)
18–49 (average: 36)	2308 (45)	986 (28)	1322 (80.7)
50—64 (average: 57)	1423 (27.5)	1156 (32.8)	267 (16.3)
>65 (average: 74)	1424 (27.6)	1371 (39)	49 (3)
Sex			
Female	2838 (54)	1626 (46)	1212 (71.4)
Male	2391 (45.8)	1906 (54)	485 (28.6)
Race/ethnicity			
White	3409 (66)	2453 (70.8)	956 (56.2)
Brown	1183 (23)	684 (19.7)	499 (29.4)
Black	445 (8.6)	244 (7)	201 (11.8)
Native Brazilian	5 (0.1)	1 (0.02)	4 (0.2)
Asian	69 (1.3)	39 (1.1)	30 (1.8)
Other	6 (0.1)	4 (0.1)	2 (0.1)
Health characteristics			
Hypertension	2185 (42)	1937 (55.3)	248 (14.7)
Cardiovascular Disease	1021 (20)	996 (29.6)	25 (1.5)
ACEi users	431 (9.5)	395 (13.7)	36 (2.2)
Asthma	239 (4.6)	172 (4.9)	67 (4)
Tabagism	1002 (19.4)	833 (24)	169 (10)
COPD	219 (4.2)	213 (6.1)	6 (0.4)
Diabetes melitus	1329 (25.7)	1238 (35.4)	91 (5.4)
HIV	35 (0.7)	33 (0.9)	2 (0.1)
CKD	449 (8.7)	441 (12.6)	8 (0.5)
BIVII STATUSO			
Obese (BMI of 30 kg/m <sup>2</sup> or greater)	1186 (32.2)	735 (36.4)	447 (26.8)
Overweight (BMI of 25–29.9 kg/m²)	1341 (36.4)	683 (33.8)	659 (39.6)
Normal (BMI of 20–24.9 kg/m <sup>2</sup> )	984 (26.7)	489 (24.2)	496 (29.8)
BMI of 20 kg/m <sup>2</sup> or lower	176 (4.8)	113 (5.6)	63 (3.8)
Cancer	191 (3.7)	170 (4.9)	21(1.2)
Autoimmune diseases	132 (2.6)	101 (2.9)	31(1.8)
Case severity			
Hospitalization	3533 (67.5)	3533 (100)	O (O)
ICU	2186 (41.8)	2186 (62.6)	O (O)
Oxygen	2621 (50.1)	2619 (75.1)	2 (0.1)
No-invasive ventilation	1263 (24.1)	1263 (36.2)	O (O)
Mechanical ventilation	1521 (29.1)	1521 (43.6)	0 (0)
Dialysis	511 (9.8)	511 (14.8)	0 (0)
Vaccination status			
Yes (2 doses)	856 (16.4)	60 (1.7)	796 (46.8)
Yes (1 dose)	102 (1.9)	58 (1.6)	44 (2.6)
No	4275 (81.7)	3415 (96.7)	860 (50.6)

435No4275 (81.7)3415 (96.7)860 (50.6)436ACEi: Angiotensin-converting enzyme inhibitors; BMI: Body Mass Index; CKD:

437 Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; HIV:

438 Human immunodeficiency virus; ICU: Intensive care unit; NA: Not available.

439

440 Table 2. Genome-wide significant and suggestive loci identified in BRACOVID Covid-

441 19 severity analysis.

CHR	BP	SNP	Effect Allele	Р	OR	Genes	
1	205208489	chr1:205208489:G:A	G	3.99E-08	1.3516	RBBP5, DSTY	K, TMCC2
2	45584979	chr2:45584979:T:C	С	4.06E-07	0.7509	SRBD1	
4	25613313	chr4:25613313:G:A	А	3.21E-07	1.4647	SLC34A2	
5	21768177	chr5:21768177:G:A	А	5.02E-07	1.3263	GUSBP1, CDI	+12
10	22439346	chr10:22439346:T:C	С	5.96E-07	0.549	PIP4K2A	

#### 443 **Figures**:

Figure 1. Manhattan plot of BRACOVID results for Covid-19 hospitalization. Results
from a logistic regression model adjusted for the first 4 PCs, age, and sex for each used
genotyping array were meta-analyzed using a fixed-effect meta-analysis.

447

448 Figure 2. Association and LD structure at Chr1 DSTYK associated locus. A. Local 449 association structure of BRACOVID hospitalization analysis; B. Local association 450 structure of HGI B2 analysis; C. Local association structure for BRACOVID European 451 cluster; D. Local association structure for BRACOVID African cluster; E. Local 452 association structure for BRACOVID Native American cluster; F. World-wide 453 distribution of pairwise LD between rs11240388 (local maximum for BRACOVID 454 analysis) and rs9661015 (local maximum for HGI B2 analysis); G. 1000G allele 455 frequency distribution for rs11240388.

456 Figure 3. Annotation and functional characterization of Chr1 DSTYK associated region. 457 A. Genomic anatomy of associated region. Blue highlight – 79Kb associated haplotype. 458 B. Phewas results and colocalization analysis with BRACOVID summary statistics. 459 Colocalization values are depicted as a function of their H3 and H4 posterior 460 probabilities. Positive values (blue spectrum) for higher H4 values than H3, negative 461 values (red spectrum) for higher H3 than H4. Inner circle represents study/database of 462 trait being colocalized with BRACOVID results. Black: Datasets that satisfy minimum 463 requirements imported from the EBI database of complete GWAS summary data; red: 464 eqtlGen 2019 results; green: GWAS summary datasets generated by many different 465 consortia that have been manually collected and curated, initially developed for MR-Base 466 (round 2); dark blue: Complete GWAS summary data on protein levels as described by 467 Sun et al 2018; magenta: Complete GWAS summary data on brain region volumes as 468 described by Elliott et al 2018; pink: Neale lab analysis of UK Biobank phenotypes, 469 round 2; C. Association structure between rs11240388 and genes within its genomic 470 region using 42 tissues in GTEx V8. Red rectangles are for association p values below 471 0.01. Numbers within cells represent the normalized mean expression value within tissue 472 for gene; D. Colocalization results between BRACOVID summary statistics for 473 rs11240388 region and different GTEx V8 gene/tissue combinations. Shown are only the 474 most significant H4 probability results; E. Causal diagram derived from pairwise 475 comparisons with significant colocalization at rs11240388 region.

476

### 477 Supplementary Figures:

478 Supplementary Figure 1. Local association plots for the 4 suggestive associated loci.
479 Suggestive association was defined as a p-value between 1 x 10-6 and 5 x 10-8. Genome
480 positions in Hg19.

481 Supplementary Figure 2. K-means clustering (k=3) of BRACOVID participants using
482 the first and second PCs. Orange triangle - European cluster; Green circle – African
483 cluster; Purple square – Native American cluster.

484 Supplementary Figure 3. Manhattan plots of ancestry clusters and trans-ethnic meta-

485 analysis. A. European cluster; B. African cluster; C. Native American cluster; D. Native
486 American cluster.

487 **Supplementary Figure 4.** Local association structure for Chr6 FOXP4 region.

488 Supplementary Figure 5. Pairwise colocalization results for all pairwise combinations 489 of significant GTEx gene/tissue pairs, traits associated with rs11240388 in the phewas 490 analysis and BRACOVID hospitalization results for the rs11240388 region. Red

491	spectrum for colocalization results where H3 posterior probability > H4 posterior
492	probability. Blue spectrum for colocalization results where H4 posterior probability > H3
493	posterior probability.

495	Supp	lement	arv	files
170	~ ~ pp		~~ J	

- 496 Supplementary File 1. Replication results from BRACOVID for HGI B1 analysis497 genome-wide significant loci.
- 498 Supplementary File 2. Replication results from BRACOVID for HGI B2 analysis
- 499 genome-wide significant loci.
- 500 Supplementary File 3. Genome-wide significant hits from meta-analysis BRACOVID
- 501 versus HGI B1 model.
- 502 Supplementary File 4. Genome-wide significant hits from meta-analysis BRACOVID
- 503 versus HGI B2 model.
- 504

























Chromosome

6:41512355



0

HGI B1 model

Meta-analysis

**BRACOVID Hospitalization** 

